



Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022

July 21, 2022

--Conference call to occur at 4:30pm ET on August 4--

EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, announced that it will host a conference call and webcast at 4:30pm ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results, and provide a corporate update.

To access the conference call, dial 800-263-0877 five minutes prior to the start of the call and provide the event title: Gritstone bio Second Quarter 2022 Earnings Call, or the following passcode: 8108859.

To access the webcast, visit https://event.webcasts.com/starthere.jsp?ei=1561514&tp_key=4f6eab0ea9

The archived webcast will be available on Gritstone's website at <http://ir.gritstonebio.com/investors/events> shortly following the conference call and will be available for at least 30 days following the call.

About Gritstone

Gritstone is working to create the world's most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets and have programs in viral diseases and solid tumors. Independently and with our partners, we are advancing a portfolio of product candidates with the aim of improving patient outcomes and eliminating disease. www.gritstonebio.com

Gritstone Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone's therapeutic programs; the advancements in the company's ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone's programs' clinical stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone's most recent Quarterly Report on Form 10-Q filed on May 5, 2022 and any current and periodic reports filed with the Securities and Exchange Commission.

Gritstone Contacts

Investors:

George E. MacDougall
Director, Investor Relations & Corp Comms
Gritstone bio, Inc.
ir@gritstone.com

Media:

Ashlea Kosikowski
1AB
ashlea@1abmedia.com

